[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640755":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":34,"responsibleParty":52,"collaborators":55,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":20,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":82,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","TearCare® eyelid warming and manual gland expression performed once at Visit 1 and followed for 4 weeks. All participants will undergo standardized ocular assessments including OSDI questionnaires, non-invasive keratograph break-up time, Visual acuity high contrast, Biomicroscopy, posterior lid margin hyperemia, Fluorescein tear breakup time, corneal fluorescein staining, conjunctival staining with lissamine green, lid wiper epitheliopathy with lissamine green, Surveys - DEQS, SANDE, Screen time-use, Lipview 11 lipid imaging, Keratograph R-scan, Keratogrpahy meibography, meiobomian gland expression by meibomian gland evaluator.",[13],"Device: TearCare®",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","TearCare®","The TearCare system is designed to deliver controlled, precise heat to the tarsal plates and underlying MGs of the eyelids for 15 minutes. The TearCare system is comprised of a reusable SmartHub and single-use SmartLids. The single-use SmartLid pair comprises four flexible, sensor-controlled strips that adhere to each of the four eyelids. They contain flexible circuits, sensors, and a microprocessor which provide accurate and precise thermal energy to the eyelids to melt oil in the meibomian glands. Medical grade adhesive on the skin-facing surface of the SmartLids allow them to be affixed to the external surface of the eyelids during the procedure and easily removed at the end of the procedure. The SmartLids are connected to the SmartHub. When attached to the SmartHub, the SmartLids deliver thermal energy (i.e., heat) to the eyelids. Embedded software and a closed loop sensor system ensures that the temperature delivered at the eyelids is maintained within a precise range.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Jillian F Ziemanski, OD, PhD, FAAO","The University of Alabama at Birmingham, School of Optometry","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Sindhu Gurrala, BDS, MPH","CONTACT","205-975-3881","SOeyes@uab.edu",{"name":33,"role":29,"phone":20,"phoneExt":20,"email":31},"UAB Optometry Clinical Research (205) 934-6734",[35],{"facility":36,"status":20,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"University of Alabama at Birmingham, School of Optometry, Clinical Eye Research Facility","Birmingham","Alabama","35294","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-86.80249,33.52066,{"lat":46,"lon":45},[49,51],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":50},"sgurral2@uab.edu",{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":25,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Jillian Ziemanski","Associate Professor",[56],{"name":57,"class":58},"Sight Sciences, Inc.","INDUSTRY","100640755","tearcare-in-young-adults-100640755",false,"NCT07579156","TearCare in Young Adults","Inclusion Criteria:\n\n1. Age ≥18 years but \\\u003C30 years of age\n2. Non-invasive Keratograph break-up time (NIKBUT) \\\u003C10 seconds in at least one eye\n3. Meibomian gland secretion score (MGSS) ≤23 for 15 glands in at least one eyelid\n4. OSDI ≥23\n\nExclusion Criteria:\n\n1. Contact lens wear within two weeks of study enrollment or planned during study period\n2. Habitual visual acuity worse than 0.30 logMAR (Snellen equivalent of 20\u002F40) in either eye\n3. Previous or current diagnosis of any autoimmune condition\n4. Use of any of the following medications within 60 days of enrollment:\n\n   1. Topical ophthalmic cyclosporine (including but not limited to Restasis®, Cequa®, Vevye®, generic, or compounded versions)\n   2. Xiidra®\n   3. Miebo®\n   4. Tyrvaya®\n   5. Tryptyr®\n5. Use of topical ocular steroids within 30 days of enrollment\n6. Use of any other topical ophthalmic drop, excluding artificial tears, within 7 days\n7. Use of oral tetracyclines or oral azithromycin within 30 days\n8. Present or past use of oral isotretinoin\n9. Any of the following procedural treatments for MGD in the past:\n\n   1. LipiFlow®\n   2. TearCare®\n   3. iLux®\n   4. Intense pulsed light (IPL)\n10. Previous intraocular surgery within 6 months of enrollment\n11. Previous refractive surgery within 2 years of enrollment\n12. Current or planned pregnancy during the study period\n13. Current or planned lactation during the study period\n14. Females of childbearing potential who are not using effective contraception\n15. Dose modification of oral antihistamines or antidepressants within 30 days of enrollment\n16. Current enrollment or enrollment within 60 days in any other study of an investigational drug or device\n17. Clinical opinion of the study doctor based on clinical examination and\u002For participant compliance with protocol requirements","ALL","18 Years","29 Years",{"count":69,"type":70},45,"ESTIMATED","INTERVENTIONAL",[73],"NA","This study is a non-randomized, open-label, interventional trial of TearCare® eyelid warming and manual meibomian gland expression in young adults with clinically significant meibomian gland dysfunction (MGD). Intervention is with TearCare® performed at Visit 1. A single follow-up examination occurs at Day 28.",[76],"Meibomian Gland Dysfunction (Disorder)",[78,79,80,81],"Meibomian Gland Dysfunction","TearCare","Ocular Surface Inflammation","Dry Eye Disease","NOT_YET_RECRUITING","2026-05-04",{"date":85,"type":86},"2026-05-11","ACTUAL",{"date":88,"type":70},"2026-08-01",{"date":90,"type":70},"2027-12-01",{"name":5,"class":6},1]